Successfully Progressing Therapeutic Candidates from Discovery to Development Using Early Developability Assessment Tools
LIVE WEBCAST
Wednesday, March 14, 2018 at 11am EDT | 10am CDT | 3pm GMT | 4pm CET
Click to register for this free webcast »
Event Overview
The application of in-silico and in-vitro screening tools in the early-stage assessment of therapeutic candidates reduces costs, shortens time to first-in-human studies, and improves the chance of clinical success. The ability to assess the manufacturability and safety of drug candidatesbefore large investments in both time and money are madeenables drug developers to focus on the most promising candidates.

The following tools can be used to evaluate and improve protein sequence and structure to optimize product design, product quality attributes, and safety:

  • Protein engineering, humanization and deimmunization
  • Manufacturability assessment to identify risks associated with productivity and product quality
  • Aggregation prediction for monoclonal antibodies
  • Mitigation of risk via protein re-engineering supported by product expression
  • Immunogenicity risk assessment
  • Early production of candidates using proven expression systems
This webcast will provide insight on how these tools, alone or in combination, can be used to develop a de-risking strategy that supports the progression of protein therapeutics from discovery into development.
Key Learning Objectives
  • Evaluate potential risks associated with a drug candidate
  • Develop a product-specific assessment and mitigation strategy
Who Should Attend
  • Protein engineers
  • R&D
  • Translational research
  • Program management
  • Product and process development
  • Drug safety
  • Regulatory
  • CMC
  • Product manager
  • Protein discovery

Komentarze

Zostaw komentarz

Zaloguj się, by móc komentować.